Apogenix to Present at Two Upcoming International Conferences

HEIDELBERG, Germany, May 4, 2016 /PRNewswire/ -- Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that Chief Executive Officer Thomas Hoeger, Ph.D., will present at Bio€quity Europe 2016 and at the Jefferies 2016 Healthcare Conference.

Bio€quity Europe 2016
Venue: Scandic Hotel, Copenhagen, Denmark
Presentation: May 10, 2016, 4:40 p.m. CEST, Ball Room 2

Jefferies 2016 Healthcare Conference
Venue: New York City, NY, USA
Presentation: June 7, 2016, 8:00 a.m. EDT

About Apogenix
Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 90 million euros in financing rounds, public grants, as well as upfront and milestone payments from licensing agreements. The company is based in Heidelberg, Germany.

SOURCE Apogenix

Related Links

http://www.apogenix.com